Search research articles
Contact Us
Filters
Showing results (31-40 of 138) with videos related to
Page
of 14
Sort By:
Expert Opinion on Drug Safety
|
January 28, 2025
The emerging role of Bruton's tyrosine kinase inhibition in urticaria management
Giuseppe Lauletta, Luca Potestio, Cataldo Patruno, et al.
Journal of Asthma and Allergy
|
August 20, 2024
Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations
Luca Potestio, Cataldo Patruno, Stefano Dastoli, et al.
Clinical and Experimental Dermatology
|
August 27, 2024
Lichen planus following COVID-19 vaccination: a narrative review
Michela D'Agostino, Fabrizio Martora, Matteo Megna, et al.
Clinical, Cosmetic and Investigational Dermatology
|
February 4, 2025
Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review
Giuseppe Lauletta, Luca Potestio, Cataldo Patruno, et al.
Case Reports in Dermatology
|
October 9, 2025
An Unusual Case of Fibromatous Fibrosis in a Young Hidradenitis Suppurativa Patient
Fabrizio Martora, Luigi Coronella, Teresa Battista, et al.
Clinical, Cosmetic and Investigational Dermatology
|
November 29, 2023
Herpes Zoster and COVID-19 Vaccination: A Narrative Review
Luca Potestio, Matteo Megna, Alessia Villani, et al.
Medicina (Kaunas, Lithuania)
|
April 28, 2023
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
Fabrizio Martora, Massimiliano Scalvenzi, Angelo Ruggiero, et al.
Journal of Clinical Medicine
|
July 27, 2022
Reply to Borgia et al. Comment on "Marasca et al. Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. <i>J. Clin. Med.</i> 2022, <i>11</i>, 1511"
Luca Potestio, Luigi Fornaro, Fabrizio Martora, et al.
Journal of Clinical Medicine
|
May 13, 2023
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study
Matteo Megna, Angelo Ruggiero, Teresa Battista, et al.
Medicina (Kaunas, Lithuania)
|
June 27, 2024
Unaddressed Challenges in the Treatment of Cutaneous Melanoma?
Alessia Villani, Luca Potestio, Aimilios Lallas, et al.
Page
of 14
Search research articles
Search
Showing results (31-40 of 138) with videos related to
Sort By:
Page
of 14
Expert Opinion on Drug Safety
|
January 28, 2025
The emerging role of Bruton's tyrosine kinase inhibition in urticaria management
Giuseppe Lauletta, Luca Potestio, Cataldo Patruno, et al.
Journal of Asthma and Allergy
|
August 20, 2024
Tralokinumab for the Treatment of Adult Atopic Dermatitis in Special Populations
Luca Potestio, Cataldo Patruno, Stefano Dastoli, et al.
Clinical and Experimental Dermatology
|
August 27, 2024
Lichen planus following COVID-19 vaccination: a narrative review
Michela D'Agostino, Fabrizio Martora, Matteo Megna, et al.
Clinical, Cosmetic and Investigational Dermatology
|
February 4, 2025
Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review
Giuseppe Lauletta, Luca Potestio, Cataldo Patruno, et al.
Case Reports in Dermatology
|
October 9, 2025
An Unusual Case of Fibromatous Fibrosis in a Young Hidradenitis Suppurativa Patient
Fabrizio Martora, Luigi Coronella, Teresa Battista, et al.
Clinical, Cosmetic and Investigational Dermatology
|
November 29, 2023
Herpes Zoster and COVID-19 Vaccination: A Narrative Review
Luca Potestio, Matteo Megna, Alessia Villani, et al.
Medicina (Kaunas, Lithuania)
|
April 28, 2023
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
Fabrizio Martora, Massimiliano Scalvenzi, Angelo Ruggiero, et al.
Journal of Clinical Medicine
|
July 27, 2022
Reply to Borgia et al. Comment on "Marasca et al. Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. <i>J. Clin. Med.</i> 2022, <i>11</i>, 1511"
Luca Potestio, Luigi Fornaro, Fabrizio Martora, et al.
Journal of Clinical Medicine
|
May 13, 2023
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study
Matteo Megna, Angelo Ruggiero, Teresa Battista, et al.
Medicina (Kaunas, Lithuania)
|
June 27, 2024
Unaddressed Challenges in the Treatment of Cutaneous Melanoma?
Alessia Villani, Luca Potestio, Aimilios Lallas, et al.
Page
of 14